Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis.
CTCs
circulating tumor DNA
circulating tumor cells
ctDNA
histologic transformation
liquid biopsy
small cell lung cancer
transformed SCLC
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 May 2021
08 May 2021
Historique:
received:
24
03
2021
revised:
02
05
2021
accepted:
03
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
The potential added value of liquid biopsy (LB) is not well determined in the case of small cell lung cancer (SCLC), an aggressive tumor that can occur either de novo or from the histologic transformation of non-small cell lung cancer (NSCLC). A systematic review of studies adopting LB in patients with SCLC have been performed to assess the clinical utility of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs). After a screening of 728 records, 62 studies (32 evaluating CTCs, 27 ctDNA, and 3 both) met predetermined eligibility criteria. Only four studies evaluated LB in the diagnostic setting for SCLC, while its prognostic significance was evaluated in 38 studies and prominently supported by both ctDNA and CTCs. A meta-analysis of 11 studies as for CTCs enumeration showed an HR for overall survival of 2.63 (1.71-4.05), with a potential publication bias. The feasibility of tumor genomic profiling and the predictive role of LB in terms of response/resistance to chemotherapy was assessed in 11 and 24 studies, respectively, with greater consistency for those regarding ctDNA. Intriguingly, several case reports suggest that LB can indirectly capture the transition to SCLC in NSCLC treated with EGFR tyrosine kinase inhibitors. While dedicated trials are needed, LB holds potential clinical roles in both de novo and transformed SCLC. CtDNA analysis appears the most valuable and practicable tool for both disease monitoring and genomic profiling.
Sections du résumé
BACKGROUND
BACKGROUND
The potential added value of liquid biopsy (LB) is not well determined in the case of small cell lung cancer (SCLC), an aggressive tumor that can occur either de novo or from the histologic transformation of non-small cell lung cancer (NSCLC).
METHODS
METHODS
A systematic review of studies adopting LB in patients with SCLC have been performed to assess the clinical utility of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs).
RESULTS
RESULTS
After a screening of 728 records, 62 studies (32 evaluating CTCs, 27 ctDNA, and 3 both) met predetermined eligibility criteria. Only four studies evaluated LB in the diagnostic setting for SCLC, while its prognostic significance was evaluated in 38 studies and prominently supported by both ctDNA and CTCs. A meta-analysis of 11 studies as for CTCs enumeration showed an HR for overall survival of 2.63 (1.71-4.05), with a potential publication bias. The feasibility of tumor genomic profiling and the predictive role of LB in terms of response/resistance to chemotherapy was assessed in 11 and 24 studies, respectively, with greater consistency for those regarding ctDNA. Intriguingly, several case reports suggest that LB can indirectly capture the transition to SCLC in NSCLC treated with EGFR tyrosine kinase inhibitors.
CONCLUSIONS
CONCLUSIONS
While dedicated trials are needed, LB holds potential clinical roles in both de novo and transformed SCLC. CtDNA analysis appears the most valuable and practicable tool for both disease monitoring and genomic profiling.
Identifiants
pubmed: 34066817
pii: cancers13092265
doi: 10.3390/cancers13092265
pmc: PMC8125928
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lung Cancer. 2014 Aug;85(2):314-9
pubmed: 24882383
Clin Lung Cancer. 2018 Nov;19(6):e843-e847
pubmed: 30122430
Ann N Y Acad Sci. 2008 Aug;1137:98-107
pubmed: 18837931
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
Lung Cancer. 2017 Apr;106:110-114
pubmed: 28285684
Ann Oncol. 2020 Jun;31(6):745-759
pubmed: 33506766
J Thorac Oncol. 2018 Jan;13(1):112-123
pubmed: 28951314
Med Oncol. 2013 Dec;30(4):755
pubmed: 24178178
Oncotarget. 2017 Jul 10;8(38):63846-63856
pubmed: 28969034
Am J Pathol. 2009 Aug;175(2):808-16
pubmed: 19628770
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Ann Oncol. 2016 Apr;27(4):642-7
pubmed: 26802149
Cancer Commun (Lond). 2019 Apr 18;39(1):20
pubmed: 30999954
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
ACS Appl Mater Interfaces. 2020 Feb 5;12(5):5671-5679
pubmed: 31940177
J Cancer. 2020 Feb 3;11(8):2113-2122
pubmed: 32127938
J Clin Oncol. 2018 Aug 10;36(23):2386-2394
pubmed: 29906251
Sci Rep. 2017 Mar 28;7:45351
pubmed: 28349943
Sci Rep. 2017 Mar 24;7:43464
pubmed: 28337998
Oncol Lett. 2014 May;7(5):1469-1473
pubmed: 24765158
J Thorac Oncol. 2018 Sep;13(9):1393-1399
pubmed: 29775808
Lung Cancer. 2018 Oct;124:270-278
pubmed: 30268472
Lung Cancer. 2016 Sep;99:23-30
pubmed: 27565909
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Clin Cancer Res. 2019 Aug 15;25(16):5049-5060
pubmed: 31113842
Cytometry. 2002 Jun 15;50(3):160-7
pubmed: 12116339
J Thorac Oncol. 2020 Feb;15(2):216-230
pubmed: 31629061
Nat Commun. 2018 Aug 6;9(1):3114
pubmed: 30082701
J Thorac Oncol. 2019 Aug;14(8):1447-1457
pubmed: 31063862
Nat Med. 2015 Jul;21(7):795-801
pubmed: 26030179
J Thorac Oncol. 2020 Feb;15(2):274-287
pubmed: 31655296
Lung Cancer. 2019 Sep;135:33-39
pubmed: 31447000
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
Asian Pac J Cancer Prev. 2014;15(19):8429-33
pubmed: 25339041
Respir Med Case Rep. 2018 Oct 06;25:261-263
pubmed: 30310765
Nat Cancer. 2020 Apr;1:423-436
pubmed: 33521652
J Clin Med. 2020 Nov 27;9(12):
pubmed: 33261056
Cancer Treat Rev. 2019 Feb;73:73-83
pubmed: 30682661
Lung Cancer. 2009 Jul;65(1):123-5
pubmed: 19261349
Front Oncol. 2020 May 20;10:741
pubmed: 32509576
Ann Oncol. 2019 Jul 1;30(7):1114-1120
pubmed: 31020334
Nat Med. 2014 Aug;20(8):897-903
pubmed: 24880617
Clin Cancer Res. 2019 Oct 15;25(20):6119-6126
pubmed: 31300452
Future Oncol. 2016 Mar;12(6):789-99
pubmed: 26838372
Cancer Treat Rev. 2019 Sep;79:101893
pubmed: 31499407
Cancer Discov. 2019 Oct;9(10):1372-1387
pubmed: 31416802
Tumori. 2017 May 12;103(3):242-248
pubmed: 28218384
Oncotarget. 2017 Jul 25;8(30):49044-49052
pubmed: 28467771
Front Oncol. 2014 Oct 14;4:271
pubmed: 25353007
EBioMedicine. 2016 Aug;10:117-23
pubmed: 27377626
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21083-8
pubmed: 24324171
Lancet Oncol. 2018 Sep;19(9):e470-e481
pubmed: 30191851
Lung. 2015 Apr;193(2):157-71
pubmed: 25690734
Anticancer Res. 2019 Feb;39(2):815-825
pubmed: 30711962
Sci Rep. 2018 Feb 2;8(1):2238
pubmed: 29396560
Clin Cancer Res. 2015 May 15;21(10):2244-55
pubmed: 25979931
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Ann Oncol. 2012 Nov;23(11):2937-2942
pubmed: 22689177
Ther Adv Med Oncol. 2020 Dec 18;12:1758835920974192
pubmed: 33414847
Invest New Drugs. 2017 Jun;35(3):334-344
pubmed: 28299514
Cancer. 2016 Aug 1;122(15):2371-8
pubmed: 27163943
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Chin J Cancer Res. 2018 Dec;30(6):596-604
pubmed: 30700928
Nat Rev Clin Oncol. 2017 Sep;14(9):549-561
pubmed: 28534531
EMBO Mol Med. 2018 Jun;10(6):
pubmed: 29848757
Lung Cancer. 2018 Jan;115:21-27
pubmed: 29290257
Lung Cancer. 2017 Oct;112:118-125
pubmed: 29191584
Ann Oncol. 2000 Sep;11(9):1097-104
pubmed: 11061602
Oncol Lett. 2016 Nov;12(5):4009-4012
pubmed: 27895763
Cancer Discov. 2015 Jul;5(7):713-22
pubmed: 25934077
J Clin Oncol. 2012 Feb 10;30(5):525-32
pubmed: 22253462
Oncotarget. 2016 Apr 12;7(15):20810-24
pubmed: 26989078
Science. 2020 Jul 3;369(6499):
pubmed: 32345712
J Thorac Oncol. 2012 Mar;7(3):512-9
pubmed: 22258473
Nat Commun. 2015 Mar 11;6:6377
pubmed: 25758528
Br J Cancer. 2017 Jun 27;117(1):8-14
pubmed: 28510571
JCO Precis Oncol. 2017;1:
pubmed: 31032471
Lancet Oncol. 2015 Apr;16(4):e165-72
pubmed: 25846096
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Clin Lung Cancer. 2020 Sep;21(5):e488-e492
pubmed: 32389504
Arch Med Res. 2016 Aug;47(6):454-459
pubmed: 27986125
Nat Med. 2017 Jan;23(1):114-119
pubmed: 27869802
Lung Cancer. 2018 Jun;120:113-121
pubmed: 29748005